The primary objectives of the study are to assess the relative bioavailability of the BIIB074 direct compression formulation (DCF) to the BIIB074 roller compaction formulation (RCF) and to determine the effect of a high-fat meal on the pharmacokinetics (PK) of the BIIB074 DCF. The secondary objective of the study is to assess the safety and tolerability of BIIB074 administered as the DCF following single oral dose administration in healthy participants.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
PK of BIIB074 DCF to RCF as assessed by maximum observed concentration (Cmax)
Timeframe: Day 1, 2, 3, 8, 9, 10
PK of BIIB074 DCF to RCF as assessed by area under the concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUClast)
Timeframe: Day 1, 2, 3, 8, 9, 10
PK of BIIB074 DCF to RCF as assessed by AUC from time 0 to infinity (AUC∞)
Timeframe: Day 1, 2, 3, 8, 9, 10
PK of BIIB074 DCF as assessed by Cmax
Timeframe: Day 1, 2, 3, 8, 9, 10
PK of BIIB074 DCF as assessed by AUClast
Timeframe: Day 1, 2, 3, 8, 9, 10
PK of BIIB074 DCF as assessed by AUC∞
Timeframe: Day 1, 2, 3, 8, 9, 10